Multimodality Treatment of a Colorectal Cancer Stage IV Patient with FOLFOX-4, Bevacizumab, Rigvir Oncolytic Virus, and Surgery

Simple item page
dc.contributor.authorTilgase, Andra
dc.contributor.authorOlmane, Evija
dc.contributor.authorNazarovs, Jurijs
dc.contributor.authorBrokane, Linda
dc.contributor.authorErdmanis, Romualds
dc.contributor.authorRasa, Agnija
dc.contributor.authorAlberts, Peteris
dc.date.accessioned2023-01-28T18:55:01Z
dc.date.available2023-01-28T18:55:01Z
dc.date.issued2018-05-01
dc.descriptionPublisher Copyright: © 2018 The Author(s).
dc.description.abstractColorectal cancer is one of the most commonly diagnosed cancers worldwide. The treatment consists of surgical resection, systemic chemotherapy, and new biological agents. One more recently emerging treatment option is oncolytic virotherapy. Although the use of the new treatment methods shows improved overall and progression-free survival, in general, even with the new treatments, mortality remains high and combinations of treatments should be sought to treat patients with colorectal cancer. Here we report a stage IV colorectal cancer patient who received multimodality treatment including bevacizumab, FOLFOX-4, surgery, and the oncolytic virus Rigvir. The patient shows complete pathological remission and remains stable 7.7 years after initial diagnosis. The possible benefits of combining Rigvir oncolytic virus and bevacizumab should be investigated since in vitro research suggests that anti-angiogenesis agents improve viral distribution by altering the microenvironment of the tumor.en
dc.description.statusPeer reviewed
dc.format.extent9
dc.format.extent1291276
dc.identifier.citationTilgase, A, Olmane, E, Nazarovs, J, Brokane, L, Erdmanis, R, Rasa, A & Alberts, P 2018, 'Multimodality Treatment of a Colorectal Cancer Stage IV Patient with FOLFOX-4, Bevacizumab, Rigvir Oncolytic Virus, and Surgery', Case Reports in Gastroenterology, vol. 12, no. 2, pp. 457-465. https://doi.org/10.1159/000492210
dc.identifier.doi10.1159/000492210
dc.identifier.issn1662-0631
dc.identifier.urihttps://dspace.rsu.lv/jspui/handle/123456789/10200
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=85052965757&partnerID=8YFLogxK
dc.language.isoeng
dc.relation.ispartofCase Reports in Gastroenterology
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectAngiogenesis inhibitor
dc.subjectBevacizumab
dc.subjectColorectal cancer
dc.subjectECHO-7 virus
dc.subjectMultimodality treatment
dc.subjectOncolytic virus
dc.subjectRigvir
dc.subject3.2 Clinical medicine
dc.subject1.1. Scientific article indexed in Web of Science and/or Scopus database
dc.subjectGastroenterology
dc.subjectSDG 3 - Good Health and Well-being
dc.titleMultimodality Treatment of a Colorectal Cancer Stage IV Patient with FOLFOX-4, Bevacizumab, Rigvir Oncolytic Virus, and Surgeryen
dc.type/dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/article

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Multimodality_Treatment.pdf
Size:
1.23 MB
Format:
Adobe Portable Document Format
Download

Collections

Research outputs from Pure / Zinātniskās darbības rezultāti no ZDIS Pure